Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Primary Dysautonomias 1Pancreatic Neoplasms 1Neoplasms 1Kidney Diseases 1Hypertension 1High Risk Prostate Cancer 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1238Docetaxel 1227Oxaliplatin 1184Capecitabine 1178Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 640Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Receptors, Androgen × Clear all
NCT05700903 2026-03-02

ARCH

University of Colorado, Denver

Phase 4 Completed
10 enrolled
Genitourinary

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

NCT06758882 2025-01-06

STAPLE

A.O.U. Città della Salute e della Scienza

Phase 2 Recruiting
94 enrolled
Genitourinary

High Risk Prostate Cancer

NCT02138383 2021-08-17

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
25 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡